Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of rituximab + bendamustine + mitoxantrone + dexamethasone in relapsed or refractory follicular lymphoma
2008-005687-13Phase 2Completed
- Sponsor
- GELTAMO
- Start
- Mar 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, bendamustine, mitoxantrone and dexamethasone in follicular lymphoma (FL), sponsored by GELTAMO. Started Mar 2009; status: completed.
02
Drugs
rituximabbendamustinemitoxantronedexamethasone
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2008-005687-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005687-13.